FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:1408-1409 November 9, 2000 Number 19 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Esteller, M. PubMed Citation

Traditionally, cancer treatments have been selected on the basis of tumor type, pathological features, clinical stage, the patient's age and performance status, and other nonmolecular considerations. We have generally accepted with a certain fatalism that some patients pigeonholed into a given category will have a response to a particular therapy, whereas others will not. The difference is often viewed as a matter of luck, like the result of a coin toss, but in fact, treatment response can be predicted in some cases, whereas it is close to impossible to predict the results of a coin toss. The field of pharmacogenomics, . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Lorenzi, P. L., Reinhold, W. C., Rudelius, M., Gunsior, M., Shankavaram, U., Bussey, K. J., Scherf, U., Eichler, G. S., Martin, S. E., Chin, K., Gray, J. W., Kohn, E. C., Horak, I. D., Von Hoff, D. D., Raffeld, M., Goldsmith, P. K., Caplen, N. J., Weinstein, J. N. (2006). Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Molecular Cancer Therapeutics 5: 2613-2623 [Abstract] [Full Text]  
• Brell, M., Tortosa, A., Verger, E., Gil, J. M., Vinolas, N., Villa, S., Acebes, J. J., Caral, L., Pujol, T., Ferrer, I., Ribalta, T., Graus, F. (2005). Prognostic Significance of O6-Methylguanine-DNA Methyltransferase Determined by Promoter Hypermethylation and Immunohistochemical Expression in Anaplastic Gliomas. Clin. Cancer Res. 11: 5167-5174 [Abstract] [Full Text]  
• Paz, M. F., Yaya-Tur, R., Rojas-Marcos, I., Reynes, G., Pollan, M., Aguirre-Cruz, L., Garcia-Lopez, J. L., Piquer, J., Safont, M.-J., Balana, C., Sanchez-Cespedes, M., Garcia-Villanueva, M., Arribas, L., Esteller, M. (2004). CpG Island Hypermethylation of the DNA Repair Enzyme Methyltransferase Predicts Response to Temozolomide in Primary Gliomas. Clin. Cancer Res. 10: 4933-4938 [Abstract] [Full Text]  
• Pakneshan, P., Tetu, B., Rabbani, S. A. (2004). Demethylation of Urokinase Promoter as a Prognostic Marker in Patients with Breast Carcinoma. Clin. Cancer Res. 10: 3035-3041 [Abstract] [Full Text]  
• (2004). The Future is Now: Oncology Pharmacogenetics and Pharmacogenomics Reach the Bedside: JEFFREY S. ROSS, Division of Molecular Medicine, Millennium Pharmaceuticals, Cambridge, Massachusetts 02139 and Department of Pathology, Albany Medical College, Albany, New York. Toxicol Pathol 32: 150-152  
• Campagna, J. A., Miller, K. W., Forman, S. A. (2003). Mechanisms of Actions of Inhaled Anesthetics. NEJM 348: 2110-2124 [Full Text]  
• Phillips, K. A., Veenstra, D. L., Oren, E., Lee, J. K., Sadee, W. (2001). Potential Role of Pharmacogenomics in Reducing Adverse Drug Reactions: A Systematic Review. JAMA 286: 2270-2279 [Abstract] [Full Text]  
• Buckner, J. C., Moynihan, T. J., Quinn, D. I., Schlegel, U., Ali-Osman, F., Srivenugopal, K., Sawaya, R., Esteller, M., Herman, J. G., Weinstein, J. N. (2001). The DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents. NEJM 344: 686-688 [Full Text]